Understanding the interaction between cytomegalovirus and tuberculosis in children: The way forward.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Basu Roy, Robindra
Prendergast, Andrew J
Seddon, James A
MetadataShow full item record
AbstractOver 1 million children develop tuberculosis (TB) each year, with a quarter dying. Multiple factors impact the risk of a child being exposed to Mycobacterium tuberculosis (Mtb), the risk of progressing to TB disease, and the risk of dying. However, an emerging body of evidence suggests that coinfection with cytomegalovirus (CMV), a ubiquitous herpes virus, impacts the host response to Mtb, potentially influencing the probability of disease progression, type of TB disease, performance of TB diagnostics, and disease outcome. It is also likely that infection with Mtb impacts CMV pathogenesis. Our current understanding of the burden of these 2 diseases in children, their immunological interactions, and the clinical consequence of coinfection is incomplete. It is also unclear how potential interventions might affect disease progression and outcome for TB or CMV. This article reviews the epidemiological, clinical, and immunological literature on CMV and TB in children and explores how the 2 pathogens interact, while also considering the impact of HIV on this relationship. It outlines areas of research uncertainty and makes practical suggestions as to potential studies that might address these gaps. Current research is hampered by inconsistent definitions, study designs, and laboratory practices, and more consistency and collaboration between researchers would lead to greater clarity. The ambitious targets outlined in the World Health Organization End TB Strategy will only be met through a better understanding of all aspects of child TB, including the substantial impact of coinfections.
CitationPLoS Pathog. 2021 Dec 9;17(12):e1010061. doi: 10.1371/journal.ppat.1010061.
AffiliationHZI,Helmholtz-Zentrum für Infektionsforschung GmbH, Inhoffenstr. 7,38124 Braunschweig, Germany.
The following license files are associated with this item:
- Creative Commons
- Authors: Holmes KK, Bertozzi S, Bloom BR, Jha P, Bloom BR, Atun R, Cohen T, Dye C, Fraser H, Gomez GB, Knight G, Murray M, Nardell E, Rubin E, Salomon J, Vassall A, Volchenkov G, White R, Wilson D, Yadav P
- Issue date: 2017 Nov 3
- Maturation and Mip-1β Production of Cytomegalovirus-Specific T Cell Responses in Tanzanian Children, Adolescents and Adults: Impact by HIV and Mycobacterium tuberculosis Co-Infections.
- Authors: Portevin D, Moukambi F, Mpina M, Bauer A, Haraka F, Chachage M, Metzger P, Saathoff E, Clowes P, Ntinginya NE, Rachow A, Hoelscher M, Reither K, Daubenberger CA, Geldmacher C
- Issue date: 2015
- Cytomegalovirus infection is a risk factor for tuberculosis disease in infants.
- Authors: Müller J, Tanner R, Matsumiya M, Snowden MA, Landry B, Satti I, Harris SA, O'Shea MK, Stockdale L, Marsay L, Chomka A, Harrington-Kandt R, Thomas ZM, Naranbhai V, Stylianou E, Mbandi SK, Hatherill M, Hussey G, Mahomed H, Tameris M, McClain JB, Evans TG, Hanekom WA, Scriba TJ, McShane H, Fletcher HA
- Issue date: 2019 Dec 5
- Impact of antiretroviral and tuberculosis therapies on CD4(+) and CD8(+) HIV/M. tuberculosis-specific T-cell in co-infected subjects.
- Authors: Chiacchio T, Petruccioli E, Vanini V, Cuzzi G, La Manna MP, Orlando V, Pinnetti C, Sampaolesi A, Antinori A, Caccamo N, Goletti D
- Issue date: 2018 Jun
- [Development of antituberculous drugs: current status and future prospects].
- Authors: Tomioka H, Namba K
- Issue date: 2006 Dec